SCHEMBL20119635

SCHEMBL20119635

c1cnc(CNc2ncnc3[nH]cnc23)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 2/20 0.43
▸ RECQL P46063 1/20 0.43
▸ LMNA P02545 4/20 0.39
▸ TSHR P16473 3/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CDK2 P24941 2/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ ALOX15 P16050 2/20 0.36
▸ KDR P35968 2/20 0.36
▸ TP53 P04637 2/20 0.36
▸ HTT P42858 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HIF1A Q16665 1/20 0.36
▸ PTK2 Q05397 2/20 0.35
▸ CDK1 P06493 2/20 0.35
▸ PRMT1 Q99873 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15950903 0.83 LMNA (0.38) EGFRRECQLLMNATSHRCYP1A2
SCHEMBL30850618 0.82 RECQL (0.65) EGFRRECQLLMNATSHRMAPK1
SCHEMBL15426196 0.82 RECQL (0.65) EGFRRECQLLMNATSHRMAPK1
6-Benzylaminopurine SCHEMBL37357 0.79 LMNA (0.62) EGFRLMNATSHRCYP1A2CDK2
6-Benzylaminopurine SCHEMBL28824679 0.79 LMNA (0.62) EGFRLMNATSHRCYP1A2CDK2
6-Benzylaminopurine SCHEMBL29772173 0.79 LMNA (0.62) EGFRLMNATSHRCYP1A2CDK2
6-Benzylaminopurine SCHEMBL11477799 0.78 LMNA (0.61) EGFRLMNATSHRCYP1A2CDK2
6-Benzylaminopurine SCHEMBL218732 0.78 LMNA (0.61) EGFRLMNATSHRCYP1A2CDK2
6-Benzylaminopurine SCHEMBL8378677 0.78 LMNA (0.61) EGFRLMNATSHRCYP1A2CDK2
SCHEMBL17017308 0.78 TAAR1 (0.46) EGFRRECQLLMNATSHRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 — — US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 — — US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 — — US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 — — US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 — — US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 — — US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 EGFR 4822/4885RECQL 1005/4885LMNA 639/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 EGFR 4822/4885RECQL 1005/4885LMNA 639/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 EGFR 4822/4885RECQL 1005/4885LMNA 639/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 EGFR 4822/4885RECQL 1005/4885LMNA 639/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 EGFR 4822/4885RECQL 1005/4885LMNA 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback